ATRI:NGS-Atrion Corporation

EQUITY | Medical Instruments & Equipment | Nasdaq Global Select

Last Closing

USD 847.78

Change

+21.28 (+2.57)%

Market Cap

USD 0.88B

Volume

2.54K

Analyst Target

USD 300.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Atrion Corp and its subsidiaries develop and manufacture products, for medical applications. Its medical products range from fluid delivery devices to ophthalmic and cardiovascular products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-03-21 )

Largest Industry Peers for Medical Instruments & Equipment

ETFs Containing ATRI

QQQS Invesco NASDAQ Future Gen.. 0.63 % 0.00 %

-0.36 (-1.46%)

USD 8.10M

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Equipment) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.40% 35% F 56% F
Dividend Return 0.18% 25% F 8% B-
Total Return 14.58% 35% F 55% F
Trailing 12 Months  
Capital Gain 34.57% 64% D 89% A-
Dividend Return 0.83% 60% D- 16% F
Total Return 35.40% 64% D 89% A-
Trailing 5 Years  
Capital Gain 171.90% 72% C 91% A-
Dividend Return 6.51% 60% D- 26% F
Total Return 178.41% 72% C 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 21.47% 61% D- 79% B-
Dividend Return 22.40% 61% D- 79% B-
Total Return 0.94% 60% D- 25% F
Risk Return Profile  
Volatility (Standard Deviation) 13.55% 97% N/A 80% B-
Risk Adjusted Return 165.29% 97% N/A 99% N/A
Market Capitalization 0.88B 76% C+ 77% C+

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Equipment) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 31.60 18% 9%
Price/Book Ratio 7.66 29% 14%
Price / Cash Flow Ratio 9.14 18% 9%
Price/Free Cash Flow Ratio 60.86 18% 7%
Management Effectiveness  
Return on Equity 17.02% 79% 81%
Return on Invested Capital 20.73% 89% 86%
Return on Assets 15.40% 87% 93%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector